| 2.59 -0.18 (-6.5%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.42  |
1-year : | 6.92 |
| Resists | First : | 4.64 |
Second : | 5.92 |
| Pivot price | 3.34 |
|||
| Supports | First : | 2.55 |
Second : | 2.12 |
| MAs | MA(5) : | 2.82 |
MA(20) : | 3.37 |
| MA(100) : | 4.64 |
MA(250) : | 4.29 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 1.2 |
D(3) : | 1.5 |
| RSI | RSI(14): 35.8 |
|||
| 52-week | High : | 16 | Low : | 2.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNOA ] has closed above bottom band by 20.8%. Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.81 - 2.84 | 2.84 - 2.85 |
| Low: | 2.51 - 2.54 | 2.54 - 2.56 |
| Close: | 2.55 - 2.61 | 2.61 - 2.64 |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Thu, 03 Oct 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200-Day Moving Average of $0.56 - MarketBeat
Thu, 19 Sep 2024
Sonoma Pharmaceuticals regains Nasdaq compliance - Investing.com
Wed, 11 Sep 2024
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line - AccessWire
Wed, 28 Aug 2024
Sonoma Pharmaceuticals Stockholders Decide on Key Governance Issues - TipRanks
Wed, 28 Aug 2024
Why Sonoma Pharmaceuticals (SNOA) Stock Is Moving - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -6.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.23 |
| Profit Margin | -36 % |
| Operating Margin | -34.6 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -74.7 % |
| Qtrly Rev. Growth | -1.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.47 |
| EBITDA (p.s.) | -3.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -1.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|